Search
for
Sort by
Research 91–120 of 1000+
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Alopecia areata: current concepts
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- 10 Complications Associated with PRP and Microneedling in Aesthetic Medicine
- Malassezia spp. Overgrowth in a Chinchilla Cat
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
- Botulinum toxin: Pearls & pitfalls
- C002 Vasculitis: A differential diagnostic approach
- Multiple sclerosis: Side effects of interferon beta therapy and their management
- Enhanced Effect of Platelet-Rich Plasma Containing a New Carrier on Hair Growth
- Ocular Effects of Cosmetic Products and Procedures
- Systematic review of platelet‐rich plasma in treating alopecia: Focusing on efficacy, safety, and therapeutic durability
- Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
- QR 678 & QR678 Neo Vs PRP—A randomised, comparative, prospective study
- Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review
- LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
- Systematic review of mesotherapy: a novel avenue for the treatment of hair loss
- Comprehensive clinical management of polycystic ovary syndrome.
- Valproate-induced thrombocytopenia
- Mucocutaneous side effects of antineoplastic chemotherapy
- Cutaneous drug reactions
- Chronic Skull Osteomyelitis following Skin Graft: A Case Report and Literature Review
- Injectable Ag nanoclusters-based hydrogel for wound healing via eliminating bacterial infection and promoting tissue regeneration
- Intraovarian vascular enhancement via stromal injection of platelet-derived growth factors: Exploring subsequent oocyte chromosomal status and in vitro fertilization outcomes